Other GLP-1 agonists have shown t 1/2 values of 51.6 3.2 h in monkeys (dulaglutide), 1113 h in humans (liraglutide), and 2.4 h in humans (Exenatide BID)
Contact your GP if you experience severe or persistent abdominal pain, persistent vomiting preventing fluid intake, signs of dehydration, or symptoms significantly impairing your quality of life
Some weeks, the medication feels strong
When fewer calories are eaten, the body begins to burn fat for energy
Abstract Aging is a complex biological process characterized by progressive functional decline across tissues and increased susceptibility to age-related diseases, with oxidative stress being a key contributing factor
While its not yet approved in Ireland, Retatrutide is currently in late-stage clinical trials, with availability expected from 2026 onwards